Innovent Biologics, Inc.
1801
주식 순위
#1161
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou,... Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
주가
$11.39
마지막 동기화: 2026-10-16
시가총액
$19.87B
변동 (1일)
1.48%
변동 (1년)
1.94%
국가
CN
거래 Innovent Biologics, Inc. (1801)
카테고리
Healthcare
Innovent Biologics, Inc. (1801)의 영업이익률
October 2026 기준 영업이익률 TTM: 12.02%
Innovent Biologics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 12.02%입니다. 2023년 말 기준 영업이익률은 -27.06%였습니다.
Innovent Biologics, Inc.의 영업이익률 기록 (2016 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 12.02% | -249.88% |
| 2024 | -8.02% | -70.36% |
| 2023 | -27.06% | -60.52% |
| 2022 | -68.54% | 8.26% |
| 2021 | -63.31% | 336.62% |
| 2020 | -14.50% | -90.87% |
| 2019 | -158.76% | -99.16% |
| 2018 | -18,841.75% | 365.63% |
| 2017 | -4,046.48% | 181.67% |
| 2016 | -1,436.60% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 38.59% | -96.79% |
US
|
|
| -149.01% | -112.40% |
US
|
|
| 25.57% | -97.87% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -97.60% |
NL
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.